Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
Bárdur SigurgeirssonKnut SchäkelH Chih-Ho HongIsaak EffendyWaldemar PlacekPhoebe RichDeborah KeefeGerard BruinPascal CharefRong FuIsabelle HampeleManmath PatekarPublished in: The Journal of dermatological treatment (2021)
The secukinumab 300 mg/2 mL PFS groups showed superiority versus placebo, and it was a safe, effective, and convenient option for patients with psoriasis. NCT02748863.